LRG-47 (Irgm1), also known p47GTPase, is an interferon (IFN)-?-inducible family of intracellular 47 kDa GTPases. LRG-47 has been shown to contribute to host resistance to certain intracellular pathogens, such as mycobacterial tuberculosis and toxoplasmagondii etc. We performed microarray analysis to identify differences in gene expression between mice-induced by myelin basic protein (MBP) and naive mice. Prominent upregulation of LRG-47 was observed in experimental autoimmune encephalomyelitis (EAE)-induced animal, which was confirmed by quantitative real-time PCR and Western blot. Indeed, levels of LRG-47 were robustly elevated in multiple sclerosis (MS)-affected tissue from patients and in the central nervous system (CNS) of EAE mice, especially in cells of lymphoid and mononuclear phagocyte origin. These preliminary data indicate the potential significance of LRG-47 in the pathogenesis of EAE, and possibly, MS. We hypothesize that blockade of LRG-47 may have a protective effect in EAE-induced mice. Based on our preliminary studies, we propose that mechanisms underlying LRG-47-mediated survival of autoreactive T-cells, activation of transcription factors and signal transduction mechanisms linked to a cell survival pathway (PI3-K/Akt), and dysregulation of cytokines, such as IFN-? and IL-17, contribute to the pathogenesis of EAE relevant to MS. Lastly, we propose that LRG-47, expressed by oligodendrocytes may also have potential impact on the cellular events of EAE. The proposed studies are to determine the effect of blocking LRG-47 on induction of EAE and to delineate the mechanisms underlying LRG-47-mediated molecular and cellular events in EAE, focusing on encephalitogenic CD4+ T-cells, and oligodendrocytes. Utilizing a novel genetically manipulated transgenic mouse model (genetic global deficient-LRG-47 mice (LRG-47-/-) and Cre recombinase LRG-47 deficient mice targeted to oligodendrocytes under the control of mouse proteolipid protein (myelin, Plp-LRG-47-/-) 1 promoter, we will fully address our hypothesis and establish the benefits of LRG-47 blockade as a therapeutic strategy in a mouse model of EAE. Thus, we will address these concepts experimentally according to the following specific aims: 1) to establish whether blockade of LRG-47 in encephalitogenic CD4 T cells attenuates development of EAE;2) to determine whether LRG-47-mediated survival of autoreactive T cells and activation of signal transduction [phosphoinositide 3-kinase (PI3-K)/ protein kinase (Akt)] contribute to the induction of EAE;3) to determine whether LRG-47-induced cytokine production (IFN-3 and IL-17) contributes importantly to the development of EAE, and 4) to analyze the contribution of LRG-47 in oligodendrocytes to the development of EAE.

Public Health Relevance

The goals of our proposal are to delineate new mechanisms through which LRG-47contributes to the pathogenesis of EAE, focusing on cell survival-related signal transduction, activation and termination of encephalitogenic T cell in response to MBP and regulation of cytokine production related to Th1 and Th17, oligodendrocyte function, and to establish the benefits of LRG-47 blockade as a therapeutic strategy in the EAE mouse model relevant to multiple sclerosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS065482-04
Application #
8327792
Study Section
Cellular and Molecular Biology of Glia Study Section (CMBG)
Program Officer
Utz, Ursula
Project Start
2010-08-20
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
4
Fiscal Year
2012
Total Cost
$315,131
Indirect Cost
$100,756
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Valasani, Koteswara Rao; Vangavaragu, Jhansi Rani; Day, Victor W et al. (2014) Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors. J Chem Inf Model 54:902-12
Valasani, Koteswara Rao; Carlson, Emily A; Battaile, Kevin P et al. (2014) High-resolution crystal structures of two crystal forms of human cyclophilin D in complex with PEG 400 molecules. Acta Crystallogr F Struct Biol Commun 70:717-22
Vangavaragu, Jhansi Rani; Valasani, Koteswara Rao; Gan, Xueqi et al. (2014) Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer's disease. Eur J Med Chem 76:506-16
Gan, Xueqi; Wu, Long; Huang, Shengbin et al. (2014) Oxidative stress-mediated activation of extracellular signal-regulated kinase contributes to mild cognitive impairment-related mitochondrial dysfunction. Free Radic Biol Med 75:230-40
Valaasani, Koteswara R; Sun, Qinru; Hu, Gang et al. (2014) Identification of human ABAD inhibitors for rescuing A?-mediated mitochondrial dysfunction. Curr Alzheimer Res 11:128-36
Zhang, Hongju; Wang, Yongfu; Yan, Shijun et al. (2014) Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury. Cell Death Dis 5:e1288
Vangavaragu, Jhansi Rani; Valasani, Koteswara Rao; Fang, Du et al. (2014) Determination of small molecule ABAD inhibitors crossing blood-brain barrier and pharmacokinetics. J Alzheimers Dis 42:333-44